(Q39314481)

10 September 2017

title

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade (English)

1 reference

10 September 2017

0 references

1 reference

S Kasper

1

1 reference

10 September 2017

F Breitenbuecher

2

1 reference

10 September 2017

H Reis

3

1 reference

10 September 2017

S Brandau

4

1 reference

10 September 2017

K Worm

5

1 reference

10 September 2017

J Köhler

6

1 reference

10 September 2017

A Paul

7

1 reference

10 September 2017

T Trarbach

8

1 reference

10 September 2017

K W Schmid

9

1 reference

10 September 2017

M Schuler

10

1 reference

10 September 2017

language of work or name

English

0 references

publication date

16 July 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

32

1 reference

10 September 2017

issue

23

1 reference

10 September 2017

page(s)

2873-2881

1 reference

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Bax-deficient mice with lymphoid hyperplasia and male germ cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Apaf1 is required for mitochondrial pathways of apoptosis and brain development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Targeting AKT signaling sensitizes cancer to cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.302

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.302

1 reference

Dimensions Publication ID

10 September 2017

1036749682

0 references

Fatcat ID

release_fqgvagc2ojehvcy6fmgsltxr3u

0 references

1 reference